VEGFA and macular retinal edema: Intravitreal administration of anti-VEGF agents is the preferred initial therapy for DME, with Aflibercept—a fusion protein targeting VEGF-A and Placental Growth Factor—notably enhancing retinal vessel permeability and mitigating macular edema (3–5).